Lenvakast 10mg Capsule

Lenvakast 10 mg Capsule may cause side effects, which often improve as your body adjusts to the medicine and usually don’t require medical attention. However, consult your doctor if they become difficult to manage. Side effects are:

• ​Nausea
  
• Fatigue
• Diarrhea
• Vomiting
• Headache
• Weight loss
• Loss of appetite
• Changes in taste
• Joint pain or muscle pain
• Stomach pain or discomfort
• Hypertension (high blood pressure)
• Blood clotting problems
• Kidney failure
• Heart problems
• Hypothyroidism
• Poor wound healing
• Liver toxicity or failure
• Hemorrhage (bleeding)
• Skin reactions (rash or blisters)
  

• Lenvakast 10mg capsule is a prescription-based medicine that should be administered orally after a doctor's consultation.
• It is advised to take with or without food.

• Lenvakast 10mg capsule works by blocking the action of the enzyme receptor tyrosine kinases (RTKs).
• This enzyme helps develop new blood vessels that nourish cancer cells and help them multiply.
• Lenvakast blocks the function of receptors that aid the growth of blood vessels in cancer cells.
• This helps slow the expansion of the disease to different parts of the body and eventually reduces the size of the tumor.

• It is advised not to miss any scheduled dosage of Lenvakast 10mg capsule.
• In case you miss a dose, consult your doctor immediately.
• Don't overdose to compensate for the missed one. 

• French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, Dadu R, Sherman EJ, McCue S, Foster NR, Nikiforov YE, Farias TDJ, Norman PJ, Wirth LJ.(2024). Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. Clin Cancer Res 30(17), 3757-3767 - https://pubmed.ncbi.nlm.nih.gov/38922338/
  
• Ruicci, K.M., Deng, Y., Xiao, T. et al. Real-world treatment outcomes and clinicopathologic and molecular determinants of response to first-line lenvatinib in patients with advanced follicular cell-derived thyroid cancer. (2025). BJC Rep 41(3) - https://pubmed.ncbi.nlm.nih.gov/40461800/
  
• Sharma, S., Nazar, A. H., Mishra, P., et al. (2025). A new therapeutic paradigm: Radioiodine combined with lenvatinib for radioiodine‑avid metastatic well‑differentiated thyroid cancer. Nuclear Medicine Communications - https://pubmed.ncbi.nlm.nih.gov/40165683/
  
• Soll, D., Bischoff, P., Frisch, A. et al. (2024). First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study. BMC Endocr Disord - https://pubmed.ncbi.nlm.nih.gov/38383419/
  
• Yokota T, Hamauchi S, Kawakami T, Fushiki K. (2024). Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer. Invest New Drugs 361-368 - https://pubmed.ncbi.nlm.nih.gov/38809355/
  
• Yu, Z., Leng, B., You, R., et al. (2025). Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib‑insensitive patients with unresectable hepatocellular carcinoma: A retrospective study. Investigational New Drugs, 43(1), 93–100 - https://pubmed.ncbi.nlm.nih.gov/39762642/